WO2005100553A2 - Method for assessment of cytotoxic lymphocyte activity - Google Patents
Method for assessment of cytotoxic lymphocyte activity Download PDFInfo
- Publication number
- WO2005100553A2 WO2005100553A2 PCT/US2005/013120 US2005013120W WO2005100553A2 WO 2005100553 A2 WO2005100553 A2 WO 2005100553A2 US 2005013120 W US2005013120 W US 2005013120W WO 2005100553 A2 WO2005100553 A2 WO 2005100553A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- ctl
- target
- assay
- dsred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
Definitions
- This invention pertains to a method to measure cytotoxic T lymphocyte
- CTL CTL activity based on cell-mediated cytolysis of fluorescent protein (e.g., green or red) expressing cells quantified by a common fluoro-based method, e.g., flow cytometry or fluorescence microplate-reader.
- fluorescent protein e.g., green or red
- Cytotoxic T lymphocytes are important effectors in host immune responses to tumors, intracellular pathogens and transplant rejection. This cytotoxicity is based on cell-surface antigen recognition and mediated through either release of perform and granzyme containing cytolytic granules or engagement of cell surface death receptors. See M. Barry et al, "Cytotoxic T lymphocytes: all roads lead to death," Nat. Rev. Immunol., vol. 2, pp. 401-409 (2002); and J. Lieberman, "The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal," Nat. Rev. Immunol., vol. 3, pp. 361-370 (2003).
- An efficient and accurate evaluation of CTL function with a highly sensitive and convenient assay is important not only in clinical assessment of immune dysfunction, but also for development and evaluation of therapeutic efficacy of cancer immunotherapy, viral infection and immune suppressive regimens to minimize transplant rejection.
- the JAM test directly evaluates CTL killing by measuring reduction in radioactivity of 3 H-thymidine pre-incorporated in genomic DNA from the remaining target cells not eliminated by cytotoxic T cells. See P. Matzinger, "The JAM test. A simple assay for DNA fragmentation and cell death," J. Immunol. Methods, vol. 145, pp. 185-92 (1991). Both assays measure the total radioactivity released from target cells, and both may have limited sensitivity for determining CTL activity of in vivo activated cells. Under physiological conditions, antigen-specific CTL-effector frequency of most immune responses is so low that the CTL activity often can not be reliably measured using these conventional methods without further in vitro stimulation.
- Hoppner et al "A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells," J. Immunol. Methods, vol. 267, pp. 157-163 (2002); N. Kienzle et al, "The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers," J. Immunol. Methods, vol. 267, pp. 99-108 (2002); M.R. Betts et al, "Sensitive and viable identification of antigen-specif ⁇ c CD8+ T cells by a flow cytometric assay for degranulation," J. Immunol. Methods, vol. 281, pp. 65-78 (2003); A.
- the VITAL assay was a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo," J. Immunol. Methods, vol. 285, pp. 25-40 (2004); U.S. Patent Application 2002/0115157, and U.S. Patent 6,828,091.
- the CTL activity was determined as a decrease in viable fluorophore-labeled cells or an increase in caspase substrate-positive cells.
- CTL cytotoxic T lymphocyte
- FACS green fluorescent protein
- DsRed red fluorescent protein
- FACS fluorescence microplate reader
- fluorescence microscopy Using one cell line as a target (T) to present antigen and the other, at the same number, as an internal control (reference, R), we have developed a new CTL assay based on cytolysis of these fluorescent protein-expressing targets detectable by FACS.
- the new assay is named a fluorolysometric (FL)-CTL assay.
- this FL-CTL assay can also be carried out with a more efficient and convenient fluorescence microplate reader-based determination using only target cells and CTL cells achieving sensitivity comparable to the FACS-based method.
- This FL-CTL assay was reproducibly used to determine primary CTL activity at high sensitivity when compared to other conventional assays with in vivo activated T cells against different antigens.
- this new reliable, sensitive, convenient, and economical CTL assay has broad application potentials for experimental and clinical use in different antigen and effector-target systems.
- Fig. 1A illustrates a schematic illustration of the two lentiviral vectors used for transducing P815 cells: on the left is an illustration of cppt.EF.GFP (the green fluorescence protein) and on the right is an illustration of cppt.EF.DsRed (red fluorescence protein).
- cppt.EF.GFP the green fluorescence protein
- cppt.EF.DsRed red fluorescence protein
- Fig. IB illustrates P815 cells after more than one year after transduction with either cppt.EF.GFP (left) or cppt.EF.DsRed (right) before (top) and after sorting (bottom) to a purity of more than 98% of GFP + or DsRed "1" expressing cells by FACS.
- Fig. 2A illustrates the effects of GFP or DsRed expression on viability and metabolic activity of the lentiviral vector transduced P815 cells compared with wild type P815 (control), as measured by optical density (O.D.) of a metabolized MTT substrate.
- Fig. 2B illustrates the effects of GFP or DsRed expression on long-term growth of the lentiviral vector transduced P815 cells compared with wild type P815 (control), as measured by growth in numbers plotted, against time in culture for a total of 3 weeks with a 1:5 subculture every 3 or 4 days.
- Fig. 3 illustrates FACS plots of stable P815 cell lines expressing GFP or
- DsRed loaded with HA specific MHC I peptide and used as targets (T) (GFP-HA, top panel, and DsRed-HA, bottom panel) mixed with reference cells (R) (P815-DsRed (top panels) or P815-GFP (bottom panels) at a T:R ratio of 1:1, and incubated for 4 hours with activated HA specific CTLs (as effector cells (E)) at a E:T ratio of 0:1 (left panels), 1:1 (middle panels), and 10:1 (right panels).
- T HA specific MHC I peptide and used as targets
- R reference cells
- E activated HA specific CTLs
- E effector cells
- Fig. 4A illustrates FACS plots that represent the activation status (expressed as up-regulation of CD44 and down-regulation of CD62L expression as compared to non activated cells (NT naive)) of T cells from non-transgenic mice (NT) activated by three-day culture with Con A stimulation (NT-Con A activated) and HA specific CTL effector cells activated by three-day culture with MHC-I HA peptide (Clone4-HA-activated).
- Fig. 4B illustrates a comparison of HA specific GFP + P815 target cell killing at various E:T ratios using the conventional JAM test and the FL-CTL assay, using the activated HA-specific cells or non-specific T cells of Fig. 4A.
- Fig. 4C illustrates a comparison of HA specific GFP+ P815 target cell killing at two E:T ratios (0:1 and 10:1) using the conventional 51 Cr-release assay and the FL-CTL assay, using the activated HA-specific cells or non-specific T cells of Fig. 4A.
- Fig. 4D illustrates a comparison of HA specific GFP+ P815 target cell killing at various E:T ratios and using the activated HA-specific cells or non-specific T cells of Fig. 4 A, as assayed with the FL-CTL assay after an incubation time of 4 hr and 24 hr.
- Fig. 5A illustrates the relationship between cell number and fluorescent intensity of GFP P815 cells based on fluorescence reading as determined with a microplate fluorescence reader.
- Fig. 5B illustrates the relationship between cell number and fluorescent intensity of P815 cells with DsRed as read using a microplate fluorescence reader.
- Fig. 5C illustrates a comparison between the CTL activity using a fluorescent microplate reader-based detection and the FACS-based system, using DsRed 4" P815 cells as targets in both assays.
- Fig. 6A illustrates a comparison between the hemagglutinin (HA)-specific
- CTL activity determined by the FL-CTL assay and a 51 Cr release assay of CTL cells collected from non-immunized naive mice and Vacc-HA immunized (HA-primed) mice that also received HA-specific CD8 cells from transgenic mice.
- Fig. 6B illustrates the hemagglutinin (HA)-specific CTL activity of endogenous T cells activated by Nacc-HA in cells from immunized (Primed) and non- immunized ( ⁇ a ⁇ ve) BALB/c mice.
- HA hemagglutinin
- Fig. 6C illustrates GFP specific CTL activity in splenocytes harvested from
- GFP-expressing bone marrow derived dentritic cells (GFP- BMDC), using the FL-CTL assay with GFP + P815 cells as target cells and DsRed 4" P815 cells as reference.
- the technology as described herein provides a basis for improving the reliability, accuracy, and convenience of FACS-based CTL analysis by the introduction of at least two or more similar, yet fluorophoric distinct cell lines, with one cell line as an internal reference (R) and the remaining cell lines as targets (T). Therefore, antigen-specific cytolysis is determined based on a relative ratio of T to R cells, not on the absolute nurnber of total remaining target cells. Additionally, the antigen loading to target cells can be replaced with lentiviral-mediated permanent antigen gene transfer to target cells.
- target cells transduced with an entire antigen gene or mini-gene provides flexibility in examining "bulky" CTL function against mnlti-epitopes of the same antigen or an individual epitope, respectively, depending on needs. Therefore, this new FL-CTL assay system represents a convenient, sensitive, reliable and economical approach to assess CTL activity.
- multiple antigen target cell lines could be produced. Each target cell line would display a specific antigen epitope which allows CTL function against multiple antigens or apitopes to be determined in a single reaction.
- fluorescent proteins could be selected from a group consisting of green fluorescent protein (GFP), enhanced GFP (EGFP), enhanced yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (ECFP), various red fluorescent proteins from Discosoma (DsRedl, DsRed 2, DsRed Monomer, DsRed-Express), AsRed2, HcRedl (from Heteractis crispa coral), AmCyan, Zs Yellow, ZsGreen, and AcGFP- 1. (BD Biosciences, Clontech, Palo Alto, California). See also, U.S. Patent Nos. 6,090,919; and 5,804,387.
- the various fluorescent proteins can be detected based on the different fluorescent properties, including different fluorescence wavelengths, different absorption wavelengths, and different fluorescent lifetimes.
- Increased assay incubation time was beneficial to further improve the sensitivity of this FL-CTL assay.
- antigen specific cytolysis may not be completed until a time greater than about 2 hours after the initial contact of targets with the effectors.
- Increases in the FL-CTL assay incubation time (from about 4 hours, or even greater than 5 hours up to 24 hours or longer) therefore provides more opportunities for effectors to interact with targets and, correspondingly, enhances specific cytolysis. This longer incubation time is possible with the stable, lentiviral-mediated GFP and DsRed expression in viable cells that indicate similar growth rates.
- this FL-CTL assay may also provide additional information, such as the proportion of effector and memory cells within the tested population, and be a valuable tool for studies of CTL effector and memory development and function.
- Another important feature of this FL-CTL assay is that it is not limited to
- fluorescence microplate readers can also be employed. Because the fluorescent protein expressing target cells are pre-sorted to high purity with relative narrow fluorescent protein expression ranges, their absolute fluorescent intensity is directly proportional to the number of fluorescent protein-expressing cells. Using a series of controls, various numbers of the target cells are added to different wells without addition of effector cells. These wells are incubated for the same time period as the target cells with effector cells. Thus, CTL-mediated cytolysis can be determined based on the decrease in fluorescent intensity of the wells with both target and effector cells as compared to the standard curve constructed using the fluorescence from the control wells. A linear regression may be used to calculate CTL activity.
- this detection method uses this detection method to large numbers of samples simultaneously with significant improvement in efficiency compared with FACS-based determination.
- a reference (R) cell line is optional.
- this system could use multiple target cell lines, each expressing a different fluorescent protein and displaying a specific antigen epitope. This multiple target cell system would allow CTL function against multiple antigens or epitopes to be determined in one reaction by the use of different filter systems to visualize the different proteins. This technique makes high throughput operation possible for clinical applications of large scale therapeutic evaluation and drug screening in pharmaceutical industry.
- one set of fluorescent protein- expressing reference cells can serve as an internal control for 12 different fluorescent, color "coded” targets in the same CTL assay well, especially when the number of effectors is a limiting factor. Examples of such color proteins are listed above.
- This technique m-ay also be applied to fluorescence microplate reader-based detection if filter sets are carefully designed to avoid spectral cross-interference of various fluorescent proteins.
- a potential limitation of this assay is its indiscriminate measurement of direct target cell cytolysis regardless of mediating pathways.
- this assay measures a relatively late event of cytolysis compared to some of the other assays examining relative early events, such as caspase activation or degranulation, its sensitivity within short incubation times may be inferior. However, increasing incubation time to greater than 2 hours brought the sensitivity to at least the same level as the other assays. Furthermore, it will be beneficial if this CTL assay system can be further extended to in vivo evaluation of CTL function.
- an optimal means of standardizing FACS-based CTL assay with convenience and reproducibiliry, especially in industry and clinical scale-up setting, is to have two or more easily accessible and similar cell populations (only different in fluorescent spectra) for targets and references to eliminate the needs and variability of flnorophore labeling each time before use. This will be especially valuable for clinical evaluation of patients' immune responsiveness against infectious agents, such as HIV, or improvement in immune responses against tumor antigens during immunotherapy treatment.
- ELISPOT assay a conventional CTL assays that were described earlier. All those involve lengthy (days) and tedious process.
- a more rapid, sensitive, and convenient assay system would allow timely assessment of patients' immunolog ⁇ cal status enabling prompt initiation and re-adjustment of proper treatment regimens.
- FACS-based analysis may not be generally accessible by all the laboratories, especially in clinical settings, and more importantly, FACS-based operation often limits the number of samples to be analyzed. It is, thus, of major advancement if a CTL assay, based on the same principle, can be easily determined through other methods, such as the microplate reader- based FL-CTL, capable of simultaneous multi-sample analyses without additional and tedious preparation procedures. This microplate reader based FL-CTL would also make the screening of large numbers of cytokines or immune stimulatory agents on improvement in CTL activity easier to achieve.
- T cell receptor (TCR) transgenic (Tg) mice (clone 4), whose CD8 T cells specifically recognize an MHC class I epitope of influenza hemagglutinin (HA 5 i 8 - 526 ), were originally generated at The Scripps Research Institute (La Jolla, California) and bred in the animal care facility at Louisiana State University Health Sciences Center, New La, Louisiana.
- Cppt.EF.GFP was constructed toy inserting the HIV central polypurine tract to previously modified EF.GFP as described in Y. Cui et al, "Targeting transgene expression to antigen-presenting cells derived from lentivirus- transduced engrafting human hematopoietic stem/progenitor cells," Blood, vol. 99, pp. 399- 408 (2002).
- Cppt.EF.DsRed was obtained by replacing the GFP with the DsRed2 gene (Clontech, Palo Alto, California).
- Lentiviruses were produced by co- transfection of cppt.EF.GFP or cppt.EF.DsRed with the packaging construct pCMVdl-8.4 (kindly provided by the University of Torino, Italy) and envelope pMD.G to 293T cells using a conventional calcium phosphate precipitation method as previously described (Cui et al, 2002).
- P815 mouse mastocytoma tumor cells; American Type Culture Collection, Manassas, Virginia cells were transduced with cppt.EF.GFP or cpptEF.DsRed at a multiplicity of infection (MOI) of 5.
- MOI multiplicity of infection
- the cells were sorted 5 days post-transduction to a purity of >98% using a FACSCalibur (BD Biosciences, San Jose, California). After transduction, the cells were cultured as stable lines in the absence of additional selection.
- CD44, CD62L, CD90.1 (Thy 1.1) and CD8 were purchased from Phar ingen (San Diego, California). FACS analysis was carried out using a FACSCalibur.
- HA specific cytotoxic T cells effector "E" cells.
- CTL cell s In vitro activation of hemagglutinin (HA) specific cytotoxic T cells (CTL cell s) was achieved by culturing CTL cells from clone 4 Tg mice with MHC-I HA 5I8 -5 26 specific peptide (IYSTVASSL, 10 ⁇ g/ml) for 3 days in RPMI medium supplied with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and 0.1 mM non-essential amino acids (Invitrogen, Carlsbad, California).
- FBS fetal bovine serum
- FBS fetal bovine serum
- 1 mM sodium pyruvate 1 mM sodium pyruvate
- non-essential amino acids Invitrogen, Carlsbad, California.
- In vivo activated HA specific T (CTL) cells were obtained from B ALB /c mice exposed to HA antigen for 3 days via immunization with recombinant vaccinia virus encoding HA gene (Vacc-HA, 1 X 10 7 PFU), either in the presence or absence of adoptive transfer of 2x10 6 HA specific T cells from Tg clone 4 mice.
- CTL In vivo activated HA specific T
- BM-DC bone marrow-derived dendritic cells
- GFP-speciflc CTL effectors
- Bone marrow cells harvested from BALBVc mice were transduced with lentiviral vector cppt.EF.GFP at MOI of 20 and cultured in the presence of 1000 U/ml murine granulocyte-macrophage colony-stimulating factor for 8 days following conventional procedures as described in Y.Cui et al, "Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells," Nat. Med., vol. 9, pp. 952-958 (2003).
- GFP-BMDC The mature, GFP-expressing BM-DC (GFP-BMDC) were injected in BALB/c mice subcutaneously at lxl0 6 /mouse, followed by a booster injection of the same number of cells a week later. T lymphocytes were harvested from the spleen of these mice 3 days after the second BMDC injection and used in the following CTL assay for evaluating GFP-specific CTL function.
- P815 cells either wild type or GFP transduced, were pulsed with 5 ⁇ Ci/ml 3 H-Thymidine and loaded with HA-I peptide (10 ⁇ g/ml) for 2-3 hours for use as target cells ("T"). After extensive washing, the cells were I cultured with the above activated HA-specific T cells at various effector celktarget cell (E:T) ratio for 4 hours. All the target cells were harvested using a FilterMate cell harvester (Terkin-
- HA antigen-specific cytolysis was calculated as 100% X (counts of control well - counts of experimental well)/counts of control well.
- 51 Cr release assay was carried out as described by G. Karupiah et al, "Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2," J. Immunol, vol. 144, p. 290 (1990).
- HA antigen-specific cytolysis was calculated as 100*% X (counts of experimental well - counts of basal release)/(counts of maximal releasable Cr — counts of basal release).
- New FL-CTL assay with stable fluorescent protein expressing target and reference cells to determine HA specific CTL function Either the established GFP or DsRed expressing P815 cell lines were loaded with MHC I HA peptide (10 ⁇ g/ml) for 2-3 hours and used as target cells (T), while other unloaded cells were used as reference (R) cells at a T:R ratio of 1 :1.
- T target cells
- R reference cells
- the T-R mix was incubated at 37°C with various numbers of activated HA- specific T (CTL) cells (effector (E) cells) in v-bottomed 96-well plate for 4 to 24 hours.
- CTL activated HA- specific T
- E effector
- HA loaded, GFP 4" target, and DsRed 4" reference cells were mixed at a 1 : 1 ratio in a 35 mm dish and incubated with Hoechst nuclear counterstain (Molecular Probes, Eugene, Oregon) on a temperature-controlled stage of a Leica DMRXA upright, epifluorescence microscope. Effector cells, also labeled vith Hoechst dye, were added to the T (target)-R (reference) mix at E:T ratio of 20:1. Image acquisition at a rate of one frame/minute was initiated immediately upon effector addition for 3 hours through a 63X liquid immersion objective lens on the microscope, which was connected to a computer integrated Sensicam QE CCD camera.
- Filter sets optimized for detecting EGFP signal were exciter HQ480/20, dichroic Q495L, and emitter HQ510/20m.
- Optimal filter sets used for DsRed were exicter 545/30, dichroic Q570DLP, and enxitter HQ620/60m.
- Filters for detecting Hoechst dye were exciter 360/40, dichroic 400DCLP, and emitter GG420LP. All filters were purchased commercially from Chroma Technology Co. (Rockingham, Vermont). Image analyses were performed with SlidebookTM software (Intelligent Imaging Innovations, Denver, Colorado).
- the fluorescent level of the remaining target cells was determined using a Bio-Tek (Winooski, Vermont) FL600 Fluorescence microplate reader.
- GFP signal was determined with a filter set of excitation wavelength at 485/20 nm and emission at 530/20 nm; and DsRed determined with a filter set of excitation at 550/20 nm and emission at 620/40 nm.
- the remaining number of GFP or DsRed targets in each well was calculated based on the standard curve constructed for each cell type.
- the antigen-specif ⁇ c cytolysis was determined as the following: (1 -number of cells in experimental well/number of cells in control well) x 100%.
- Example 2 Lentiviral vectors efficiently and stably integrated GFP and DsRed transgenes to P815 cells, without affecting cell viability or long-term growth
- lentiviral vectors were constructed that expressed either enhanced green fluorescence protein (EGFP) or red fluorescence protein (DsRed) driven by a promoter of the human elongation factor (EFl ), as illustrated in Fig 1A.
- Fig. 1A gives a schematic illustration of cppt.EF.GFP and cppt.EF.DsRed lentiviral vectors used for transducing P815 cells.
- P815 cells were transduced with one or the other lentivims at MOI of 5. Five days after the transduction or when the transduced cells were expanded to more than 2 X 10 6 , the cells were sorted to GFP 4" or DsRed 4" cells at a purity of >98% (Fig. IB). Their purity and fluorescence intensity remained unchanged in long-term culture without additional selection, and were subsequently used as either target (T) or reference cells (R) (Fig. IB).
- Lentiviral-transduced GFP or DsRed expressing cells were cultured for 3 weeks with 1:5 subculture every 3-4 days, and their growth expressed in fold of expansion in log scale was plotted against time in culture. The data are shown in Fig. 2B, where each point is an average of 3 separate experiments with triplicate samples for each experiment. As shown in Fig. 2B, during the 3-week culture, the proliferation rate and viability of GFP 4" or DsRed 4" P815 cells were also not affected by the transgene expression. Thus, these two transduced cell lines behaved almost identically to each other and to the wild type in culture. This means that the cells would maintain a relatively constant ratio when mixed in both short- term and long-term culture conditions.
- Example 3 HA-antigen specific cytolysis of transgene expressing P815 target can be efficiently determined by FACS analysis and visualized by fluorescent microscopy (FL-CTL assay)
- GFP 4" or DsRed 4" cells were loaded with an influenza hemagglutinin (HA) MHC class I peptide (10 ⁇ g/ml) as target (T). These loaded cells were then mixed with non-peptide loaded fluorescent protein (DsRed 4" or GFP + , respectively) expressing cells used as reference (R) at a 1:1 ratio.
- This T (target)-R (reference) mix was cultured with various numbers of in vitro activated HA specific CTL effectors (E) in a V-bottomed 96-well plate for 4 hours.
- Fig. 3 shows the stable P815 cell lines expressing GFP or DsRed that were loaded with HA specific MHC I peptide and used as targets (T) (GFP-HA, top and Red-HA, bottom, respectively) in CTL assays.
- the cells were mixed with reference cells P815-DsRed (top panels) or P815-GFP (bottom panels) at a 1:1 ratio and incubated with activated HA-specific CTLs (effector cells; E) at three E:T ratios of 0:1, 1:1, and 10:1. At the end of 4-hour incubation, these cells were harvested for FACS analysis, and all viable P815 cells were gated based on their size to determine changes in percentage of target cells vs. reference cells. HA specific cytolysis was calculated as (1 -experimental T-R ratio/control T- R ratio) X 100%.
- Fig. 3 represents FACS plots of five individual experiments.
- a Hoechst dye was used to label nuclei at the blue fluorescent spectrum to simultaneously visualize effectors (blue only), GFP + target (green and blue), and DsRed 4" reference (red and blue) cells (Data Not Shown).
- the cell-cell interaction was monitored and images captured at 1 minute/frame for 3 hours with a computer integrated CCD camera.
- brief contacts of HA-specific effectors with both GFP + and DsRed 4" cells occurred almost immediately upon the addition of effector cells.
- obvious changes such as chromatin condensation and bleb formation (i.e. signs of apoptosis), were only observed in HA-presenting GFP 4" cells starting at around 1 hour after the initial interaction.
- CTL assay were comparable to those of conventional assays, two types of activated CTL cells were prepared, Con-A stimulated HA non-specific CTL cells from non-transgenic (NT) mice and HA peptide-stimulated CTL cells from TCR transgenic mice (clone4), whose activation was confirmed by up-regulation of CD44 and down-regulation of CD62L.
- CTL cells from non-transgenic mice (NT) were activated via 3 -day Con A stimulation, and HA specific CTL effectors were activated by MHC-I HA peptide in 3 -day culture.
- the CTL cell activation status was characterized as up-regulation of CD44 or down-regulation of CD62L expression compared to non-activated cells.
- the FL-CTL assay was also compared with the conventional 51 Cr release assay in determining CTL activity of in vitro activated HA specific T cells at the E:T ratios of 0: 1 and 10:1.
- Figs. 4C and 4D were generated under slightly different conditions, and thus CTL activity, expresses as percentage, may be different. As shown in Fig. 4C, the new FL-CTL assay is more sensitive than the conventional 5 Cr assay. Fig. 4D indicates that FL-CTL sensitivity can be enhanced by increasing the assay incubation time.
- Example 5 Antigen specific cytolysis with the FL-CTL assay determined via a fluorescence microplate reader
- This FL-CTL assay is sensitive and convenient for evaluation of in vivo activated antigen specific CTL in different antigen systems without further in vitro stimulation
- in vivo activated T cells are usually found at a much lower frequency than in vitro activated T cells, their further in vitro expansion/stimulation is usually required before CTL function can be evaluated with conventional assays.
- first naive HA specific T cells were adoptively transferred from clone 4 Tg mice to non-transgenic mice and then immunized with 1 X 10 7 vaccinia virus expressing HA antigen (Vacc-HA, HA-primed). Three days after activation with Vacc-HA, in vivo activated HA specific T cells (splenocytes) were harvested from the mice.
- the FL-CTL assay always indicated higher CTL lysis than when compared with that determined by 51 Cr release assay (Fig. 6A).
- the specific killing % for the FL-CTL assay was about 90%, while the 51 Cr release assay only indicated about 50%.
- T cells were harvested from Vacc-HA immunized mice in the absence of adoptive transfer of HA specific CTL cells, and used as effector cells (E). Again, HA-loaded GFP 4" cells were used as targets (T), and the FL-CTL assay was done using E:T ratios from 1:1 to 100:1.
- this FL-CTL assay system can be generally applied to examine CTL function against other defined antigens, such as GFP
- BALB/c mice were primed and boosted withl X 10 6 lentiviral vector GFP transduced bone marrow derived dendritic cells (GFP-BMDC), each time at 7 days apart.
- GFP-BMDC lentiviral vector GFP transduced bone marrow derived dendritic cells
- Another group of mice were injected twice with the same number of mock-transduced BMDC.
- CTL cells splenocytes
- GFP specific CTL cells were examined using GFP 4" P815 cells as target and DsRed " P815 cells as reference with two mice in each group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002562839A CA2562839A1 (en) | 2004-04-16 | 2005-04-14 | Method for assessment of cytotoxic t lymphocyte activity |
| US11/578,477 US20070224660A1 (en) | 2004-04-16 | 2005-04-14 | Method for Assessment of Cytotoxic T Lymphocyte Activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56304304P | 2004-04-16 | 2004-04-16 | |
| US60/563,043 | 2004-04-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005100553A2 true WO2005100553A2 (en) | 2005-10-27 |
| WO2005100553A3 WO2005100553A3 (en) | 2006-03-16 |
Family
ID=35150552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/013120 Ceased WO2005100553A2 (en) | 2004-04-16 | 2005-04-14 | Method for assessment of cytotoxic lymphocyte activity |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20070224660A1 (en) |
| CA (1) | CA2562839A1 (en) |
| WO (1) | WO2005100553A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105445171A (en) * | 2016-01-08 | 2016-03-30 | 王昭 | Flow cytometry detection method of natural killer cell degranulation |
| CN105547971A (en) * | 2016-01-08 | 2016-05-04 | 王昭 | Flow-cytometry detecting method of cytotoxic-T-lymphocyte degranulation |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012022557A1 (en) * | 2010-08-17 | 2012-02-23 | Siemens Healthcare Diagnostics Inc. | Reference sample for quality control in molecular diagnosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5000362A (en) * | 1989-06-02 | 1991-03-19 | Nuova Sanac S.P.A. | Shut-off device made of refractory material for a slide-gate pouring appliance |
| WO2002012545A2 (en) * | 2000-08-03 | 2002-02-14 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
| EP1349569B1 (en) * | 2001-01-12 | 2007-04-18 | Becton Dickinson and Company | Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof |
-
2005
- 2005-04-14 WO PCT/US2005/013120 patent/WO2005100553A2/en not_active Ceased
- 2005-04-14 CA CA002562839A patent/CA2562839A1/en not_active Abandoned
- 2005-04-14 US US11/578,477 patent/US20070224660A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| CHEN K. ET AL: 'FL-CTL assay:fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells' JOURNAL OF IMMUNOLOGICAL METHODS vol. 300, no. 1-2, May 2005, pages 100 - 114, XP004933611 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105445171A (en) * | 2016-01-08 | 2016-03-30 | 王昭 | Flow cytometry detection method of natural killer cell degranulation |
| CN105547971A (en) * | 2016-01-08 | 2016-05-04 | 王昭 | Flow-cytometry detecting method of cytotoxic-T-lymphocyte degranulation |
| CN105445171B (en) * | 2016-01-08 | 2018-03-02 | 首都医科大学附属北京友谊医院 | The flow cytometry assays of NK degranulation |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070224660A1 (en) | 2007-09-27 |
| WO2005100553A3 (en) | 2006-03-16 |
| CA2562839A1 (en) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220062398A1 (en) | Long chain antigen containing interepitope sequence that promotes antigen presentation to t cells | |
| JP4511033B2 (en) | Method for screening for bioactive agents capable of altering cell phenotype using FACS | |
| JP7711049B2 (en) | High-throughput methods for screening cognate T cell and epitope reactivity in primary human cells | |
| Wang et al. | Optimized protocols for γδ T cell expansion and lentiviral transduction | |
| CN106574292A (en) | Method for Distinguishing Desired Cell Types Using Expression of miRNAs as Indicators | |
| Rothaeusler et al. | Assessment of cell proliferation by 5‐bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry | |
| EP4048291A1 (en) | Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells | |
| CN107904278B (en) | Method for detecting influence of drug on cell proliferation | |
| Chen et al. | FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells | |
| Sadtler et al. | Analyzing the scaffold immune microenvironment using flow cytometry: practices, methods and considerations for immune analysis of biomaterials | |
| Afeyan et al. | Rapid parallel reconstruction and specificity screening of hundreds of T cell receptors | |
| JP4388372B2 (en) | Production of cultured human mast cells and basophils for high-throughput small molecule drug discovery | |
| US20220228164A1 (en) | Engineered antigen presenting cells | |
| US20070224660A1 (en) | Method for Assessment of Cytotoxic T Lymphocyte Activity | |
| US20200299340A1 (en) | Fusion proteins comprising detectable tags, nucleic acid molecules, and method of tracking a cell | |
| WO2023019583A1 (en) | Method for detecting and sorting antigen-specific t-cell receptor with high throughput | |
| CN117761308B (en) | Marker combination for screening target antigen-specific T cells and its use | |
| Poggi | Generation of tumor spheroids to evaluate T cell and NK cell cytotoxicity | |
| EP4227423A1 (en) | Means and methods for identifying high affinity t-cells | |
| Park et al. | Fusion of the Human Cytomegalovirus pp65 antigen with both ubiquitin and ornithine decarboxylase additively enhances antigen presentation to CD8+ T cells in human dendritic cells | |
| WO2024092740A1 (en) | Method for detecting intercellular interaction and use thereof | |
| JPWO2006040920A1 (en) | CTL inducibility evaluation method and screening method using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2562839 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11578477 Country of ref document: US Ref document number: 2007224660 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WWP | Wipo information: published in national office |
Ref document number: 11578477 Country of ref document: US |